ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Revenue of ALK-Abelló A/S (ALK-B.CO)
Revenue in 2023 (TTM): $699.89 M
According to ALK-Abelló A/S's latest financial reports the company's current revenue (TTM) is $699.89 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ALK-Abelló A/S
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $699.89 M | $440.33 M | $132.61 M | $93.87 M | $70.51 M |
| 2022 | $654.48 M | $404.93 M | $102.87 M | $64.85 M | $48.6 M |
| 2021 | $568.15 M | $347.62 M | $78.93 M | $40.48 M | $31.77 M |
| 2020 | $506.49 M | $294.23 M | $55.28 M | $14.65 M | $3.63 M |
| 2019 | $475.01 M | $274.5 M | $35.98 M | $-4,497,642 | $-7,254,261 |
| 2018 | $422.92 M | $236.92 M | $23.21 M | $-14,943,778 | $-24,664,487 |
| 2017 | $422.2 M | $238.23 M | $33.95 M | $-17,700,397 | $-22,923,465 |
| 2016 | $435.98 M | $291.77 M | $105.48 M | $70.66 M | $39.17 M |
| 2015 | $372.72 M | $251.43 M | $83.28 M | $58.03 M | $49.91 M |
| 2014 | $352.99 M | $246.21 M | $71.09 M | $43.53 M | $26.26 M |
| 2013 | $325.57 M | $224.45 M | $35.4 M | $15.09 M | $8.85 M |
| 2012 | $340.22 M | $246.21 M | $45.27 M | $16.39 M | $7.83 M |
| 2011 | $340.66 M | $252.01 M | $63.26 M | $46.57 M | $29.02 M |
| 2010 | $310.48 M | $215.74 M | $44.69 M | $30.03 M | $18.57 M |
| 2009 | $280.74 M | $195.57 M | $40.19 M | $27.57 M | $17.12 M |
| 2008 | $258.83 M | $182.37 M | $35.55 M | $22.78 M | $13.78 M |
| 2007 | $239.68 M | $167.28 M | $45.85 M | $33.66 M | $20.31 M |
| 2006 | $216.03 M | $143.92 M | $24.23 M | $13.49 M | $3.48 M |
| 2005 | $176.57 M | $116.65 M | $10.3 M | $-9,575,624 | $624.16 M |
| 2004 | $ | $ | $ | $ | $ |
| 2003 | $ | $ | $ | $ | $ |
| 2002 | $ | $ | $ | $ | $ |